Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 482-491

  Teipel, Stefan ^a,b   Heinsen, Helmut ^c   Amaro, Edson ^d   Grinberg, Lea T ^d,e   Krause, Bernd ^a   Grothe, Michel ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid PET; Cholinergic system; Diagnosis; Hippocampus; Predementia Alzheimer's disease

Indexed keywords

AMYLOID; FLORBETAPIR F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CHOLINERGIC BASAL FOREBRAIN ATROPHY; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

AMYLOID PET; CHOLINERGIC SYSTEM; DIAGNOSIS; HIPPOCAMPUS; PREDEMENTIA ALZHEIMER'S DISEASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; CEREBRAL CORTEX; CHOLINERGIC NEURONS; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; PROSENCEPHALON;

EID: 84889572209     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.029     Document Type: Article

References (90)

1. Apostolova L.G., Hwang K.S., Andrawis J.P., Green A.E., Babakchanian S., Morra J.H., Cummings J.L., Toga A.W., Trojanowski J.Q., Shaw L.M., Jack C.R., Petersen R.C., Aisen P.S., Jagust W.J., Koeppe R.A., Mathis C.A., Weiner M.W., Thompson P.M. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol. Aging 2010, 31:1284-1303.
2. Arendt T., Bigl V., Tennstedt A., Arendt A. Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease. Neurosci. Lett. 1984, 48:81-85.
3. Ashburner J. Afast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
4. Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 2005, 132:73-86.
5. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., Hiemeyer F., Wittemer-Rump S.M., Seibyl J., Reininger C., Sabri O. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011, 10:424-435.
6. Beach T.G. Physiologic origins of age-related beta-amyloid deposition. Neurodegener. Dis. 2008, 5:143-145.
7. Beach T.G., Kuo Y.M., Spiegel K., Emmerling M.R., Sue L.I., Kokjohn K., Roher A.E. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J.Neuropathol. Exp. Neurol. 2000, 59:308-313.
8. Becker J.A., Hedden T., Carmasin J., Maye J., Rentz D.M., Putcha D., Fischl B., Greve D.N., Marshall G.A., Salloway S., Marks D., Buckner R.L., Sperling R.A., Johnson K.A. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann. Neurol. 2011, 69:1032-1042.
9. Boncristiano S., Calhoun M.E., Kelly P.H., Pfeifer M., Bondolfi L., Stalder M., Phinney A.L., Abramowski D., Sturchler-Pierrat C., Enz A., Sommer B., Staufenbiel M., Jucker M. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J.Neurosci. 2002, 22:3234-3243.
10. Bourgeat P., Chetelat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127.
11. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 1997, 18:351-357.
12. Chetelat G., Villemagne V.L., Bourgeat P., Pike K.E., Jones G., Ames D., Ellis K.A., Szoeke C., Martins R.N., O'Keefe G.J., Salvado O., Masters C.L., Rowe C.C. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann. Neurol. 2010, 67:317-324.
13. Chetelat G., Villemagne V.L., Pike K.E., Baron J.C., Bourgeat P., Jones G., Faux N.G., Ellis K.A., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C.L., Rowe C.C. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358.
14. Christensen D.Z., Bayer T.A., Wirths O. Intracellular Abeta triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 2010, 31:1153-1163.
15. Counts S.E., Nadeem M., Wuu J., Ginsberg S.D., Saragovi H.U., Mufson E.J. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann. Neurol. 2004, 56:520-531.
16. Csernansky J.G., Hamstra J., Wang L., McKeel D., Price J.L., Gado M., Morris J.C. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis. Assoc. Disord. 2004, 18:190-195.
17. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999, 281:1401-1406.
18. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., Cochran E.J., Kordower J.H., Mufson E.J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 2002, 51:145-155.
19. Desikan R.S., Segonne F., Fischl B., Quinn B.T., Dickerson B.C., Blacker D., Buckner R.L., Dale A.M., Maguire R.P., Hyman B.T., Albert M.S., Killiany R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006, 31:968-980.
20. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
21. Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol. 2011, 121:145-147.
22. Fleisher A.S., Chen K., Liu X., Roontiva A., Thiyyagura P., Ayutyanont N., Joshi A.D., Clark C.M., Mintun M.A., Pontecorvo M.J., Doraiswamy P.M., Johnson K.A., Skovronsky D.M., Reiman E.M. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 2011, 68:1404-1411.
23. Geula C., Nagykery N., Nicholas A., Wu C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J.Neuropathol. Exp. Neurol. 2008, 67:309-318.
24. Grinberg L.T., Rub U., Ferretti R.E., Nitrini R., Farfel J.M., Polichiso L., Gierga K., Jacob-Filho W., Heinsen H. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathol. Appl. Neurobiol. 2009, 35:406-416.
25. Grothe, M., Ewers, M., Krause, B., Heinsen, H., Teipel, S.J. 2013. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement, in press.
26. Grothe M., Heinsen H., Teipel S. Longitudinal measures of cholinergic forebrain atrophy in the transition from healthy aging to Alzheimer's disease. Neurobiol. Aging 2013, 34:1210-1220.
27. Grothe M., Heinsen H., Teipel S.J. Atrophy of the cholinergic basal forebrain over the adult age range and in early stages of Alzheimer's disease. Biol. Psychiatry 2012, 71:805-813.
28. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
29. Haense C., Kalbe E., Herholz K., Hohmann C., Neumaier B., Krais R., Heiss W.D. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol. Aging 2012, 33:867-877.
30. Hammers A., Allom R., Koepp M.J., Free S.L., Myers R., Lemieux L., Mitchell T.N., Brooks D.J., Duncan J.S. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 2003, 19:224-247.
31. Hanley J.A., McNeil B.J. Amethod of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 1983, 148:839-843.
32. Hanseeuw B.J., Van Leemput K., Kavec M., Grandin C., Seron X., Ivanoiu A. Mild cognitive impairment: differential atrophy in the hippocampal subfields. AJNR Am. J. Neuroradiol. 2011, 32:1658-1661.
33. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J.Alzheimers Dis. 2006, 9(3 suppl):151-153.
34. Hatashita S., Yamasaki H. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. J.Alzheimers Dis. 2010, 21:995-1003.
35. Heinsen H., Hampel H., Teipel S.J. Computer-assisted 3D reconstruction of the Nucleus basalis complex, including the Nucleus subputaminalis. Brain 2006, 129:E43.
36. Herholz K., Weisenbach S., Zundorf G., Lenz O., Schroder H., Bauer B., Kalbe E., Heiss W.D. Invivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004, 21:136-143.
37. Ikonomovic M.D., Abrahamson E.E., Isanski B.A., Wuu J., Mufson E.J., DeKosky S.T. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Arch. Neurol. 2007, 64:1312-1317.
38. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Wuu J., Mathis C.A., Scheff S.W., Mufson E.J., DeKosky S.T. Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 2011, 77:39-47.
39. Iyo M., Namba H., Fukushi K., Shinotoh H., Nagatsuka S., Suhara T., Sudo Y., Suzuki K., Irie T. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997, 349:1805-1809.
40. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
41. Kendziorra K., Wolf H., Meyer P.M., Barthel H., Hesse S., Becker G.A., Luthardt J., Schildan A., Patt M., Sorger D., Seese A., Gertz H.J., Sabri O. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur. J. Nucl Med. Mol. Imag. 2011, 38:515-525.
42. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
43. Koivunen J., Scheinin N., Virta J.R., Aalto S., Vahlberg T., Nagren K., Helin S., Parkkola R., Viitanen M., Rinne J.O. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011, 76:1085-1090.
44. Kuhl D.E., Minoshima S., Fessler J.A., Frey K.A., Foster N.L., Ficaro E.P., Wieland D.M., Koeppe R.A. Invivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol. 1996, 40:399-410.
45. La Joie R., Perrotin A., Barre L., Hommet C., Mezenge F., Ibazizene M., Camus V., Abbas A., Landeau B., Guilloteau D., de La Sayette V., Eustache F., Desgranges B., Chetelat G. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J.Neurosci. 2012, 32:16265-16273.
46. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586.
47. Leanza G. Chronic elevation of amyloid precursor protein expression in the neocortex and hippocampus of rats with selective cholinergic lesions. Neurosci. Lett. 1998, 257:53-56.
48. Mann D.M., Yates P.O., Marcyniuk B. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment. Mech. Ageing Dev. 1984, 25:189-204.
49. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
50. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn. Mem. 2004, 11:43-49.
51. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J.Comp. Neurol. 1988, 275:216-240.
52. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J.Comp. Neurol. 1983, 214:170-197.
53. Mesulam M.M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983, 10:1185-1201.
54. Metz C.E., Herman B.A., Roe C.A. Statistical comparison of two receiver operating characteristics-curve estimates obtained from partially-paired datasets. Med. Decis. Making 1998, 18:110-121.
55. Mortimer J.A., Gosche K.M., Riley K.P., Markesbery W.R., Snowdon D.A. Delayed recall, hippocampal volume and Alzheimer neuropathology: findings from the Nun Study. Neurology 2004, 62:428-432.
56. Mufson E.J., Binder L., Counts S.E., DeKosky S.T., de Toledo-Morrell L., Ginsberg S.D., Ikonomovic M.D., Perez S.E., Scheff S.W. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 2012, 123:13-30.
57. Muller M.J., Greverus D., Weibrich C., Dellani P.R., Scheurich A., Stoeter P., Fellgiebel A. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol. Aging 2007, 28:398-403.
58. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci. 2001, 22:77-78.
59. Perry E.K., Tomlinson B.E., Blessed G., Bergman K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental testscores in senile dementia. Br. Med. J. 1978, 2:1457-1459.
60. Pluta J., Yushkevich P., Das S., Wolk D. Invivo analysis of hippocampal subfield atrophy in mild cognitive impairment via semi-automatic segmentation of T2-weighted MRI. J.Alzheimers Dis. 2012, 31:85-99.
61. Potter P.E., Rauschkolb P.K., Pandya Y., Sue L.I., Sabbagh M.N., Walker D.G., Beach T.G. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol. 2011, 122:49-60.
62. Pruessner J.C., Li L.M., Serles W., Pruessner M., Collins D.L., Kabani N., Lupien S., Evans A.C. Volumetry of hippocampus and amygdala with high-resolution MRI and three-dimensional analysis software: minimizing the discrepancies between laboratories. Cereb. Cortex 2000, 10:433-442.
63. Reitz C., Brickman A.M., Brown T.R., Manly J., DeCarli C., Small S.A., Mayeux R. Linking hippocampal structure and function to memory performance in an aging population. Arch. Neurol. 2009, 66:1385-1392.
64. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
65. Royall D.R., Palmer R.F., Petrovitch H., Ross G.W., Masaki K., White L.R. Modeling regional vulnerability to Alzheimer pathology. Neurobiol. Aging 2012, 33:1556-1563.
66. Sarazin M., Chauvire V., Gerardin E., Colliot O., Kinkingnehun S., de Souza L.C., Hugonot-Diener L., Garnero L., Lehericy S., Chupin M., Dubois B. The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. J.Alzheimers Dis. 2010, 22:285-294.
67. Sassin I., Schultz C., Thal D.R., Rüb U., Arai K., Braak E., Braak H. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol. 2000, 100:259-269.
68. Schipke C.G., Peters O., Heuser I., Grimmer T., Sabbagh M.N., Sabri O., Hock C., Kunz M., Kuhlmann J., Reininger C., Blankenburg M. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2012, 33:416-422.
69. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J.Neural Transm. 2006, 113:1625-1644.
70. Scholl M., Wall A., Thordardottir S., Ferreira D., Bogdanovic N., Langstrom B., Almkvist O., Graff C., Nordberg A. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012, 79:229-236.
71. Selden N.R., Gitelman D.R., Salamon-Murayama N., Parrish T.B., Mesulam M.M. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 1998, 121:2249-2257.
72. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol. Clin. 2000, 18:903-922.
73. Shimada H., Ataka S., Takeuchi J., Mori H., Wada Y., Watanabe Y., Miki T. Pittsburgh compound B-negative dementia: a possibility of misdiagnosis of patients with non-Alzheimer disease-type dementia as having AD. J.Geriatr. Psychiatry Neurol. 2011, 24:123-126.
74. Shin J., Lee S.Y., Kim S.J., Kim S.H., Cho S.J., Kim Y.B. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. Neuroimage 2010, 52:488-496.
75. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., Sexton G., Kaye J.A. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
76. Svensson A.L., Warpman U., Hellstrom-Lindahl E., Bogdanovic N., Lannfelt L., Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 1997, 232:37-40.
77. Teipel S.J., Bayer W., Alexander G.E., Bokde A.L., Zebuhr Y., Teichberg D., Muller-Spahn F., Schapiro M.B., Moller H.J., Rapoport S.I., Hampel H. Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol. Aging 2003, 24:85-94.
78. Teipel S.J., Ewers M., Wolf S., Jessen F., Kolsch H., Arlt S., Luckhaus C., Schonknecht P., Schmidtke K., Heuser I., Frolich L., Ende G., Pantel J., Wiltfang J., Rakebrandt F., Peters O., Born C., Kornhuber J., Hampel H. Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease. Psychiatry Res. 2010, 182:244-250.
79. Teipel S.J., Flatz W.H., Heinsen H., Bokde A.L., Schoenberg S.O., Stockel S., Dietrich O., Reiser M.F., Moller H.J., Hampel H. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 2005, 128:2626-2644.
80. Teipel S.J., Grothe M., Lista S., Toschi N., Garaci F.G., Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med. Clin. North Am. 2013, 97:399-424.
81. Teipel S.J., Meindl T., Grinberg L., Grothe M., Cantero J.L., Reiser M.F., Moller H.J., Heinsen H., Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer's disease: an invivo MRI and DTI study. Hum. Brain Mapp. 2011, 32:1349-1362.
82. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
83. Villain N., Chetelat G., Grassiot B., Bourgeat P., Jones G., Ellis K.A., Ames D., Martins R.N., Eustache F., Salvado O., Masters C.L., Rowe C.C., Villemagne V.L. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139.
84. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
85. Vogels O.J., Broere C.A., ter Laak H.J., ten Donkelaar H.J., Nieuwenhuys R., Schulte B.P. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol. Aging 1990, 11:3-13.
86. Wahlund L.O., Almkvist O., Blennow K., Engedahl K., Johansson A., Waldemar G., Wolf H. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top. Magn. Reson. Imaging 2005, 16:427-437.
87. Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J., Jennings R.G., Karow D., Dale A.M. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am. J. Neuroradiol. 2010, 31:347-354.
88. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., Delong M.K. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
89. Yushkevich P.A., Wang H., Pluta J., Das S.R., Craige C., Avants B.B., Weiner M.W., Mueller S. Nearly automatic segmentation of hippocampal subfields in invivo focal T2-weighted MRI. Neuroimage 2010, 53:1208-1224.
90. Zaborszky L., Hoemke L., Mohlberg H., Schleicher A., Amunts K., Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 2008, 42:1127-1141.